A triplet combination of azacitidine-venetoclax with PD-1 inhibitor nivolumab to further enhance the response rates and duration of response in frontline older AML not fit for traditional induction and relapsed/refractory AML is being investigated (NCT02397720). Here, PDCD1 is linked to acute myeloid leukemia.